or Try an Advanced Search...

    Regeneron Stocks List

    Symbol Grade Name % Change
    SNY B Sanofi 0.66
    REGN B Regeneron Pharmaceuticals, Inc. -1.97
    ADVM F Adverum Biotechnologies, Inc. 4.24
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development

    Related ETFs - A few ETFs which own one or more of the above listed Regeneron stocks.

    Symbol Grade Name Weight
    IBBQ B Invesco Nasdaq Biotechnology ETF 9.66
    FPX C First Trust IPOX-100 Index Fund 9.18
    IBB B iShares Nasdaq Biotechnology Index Fund 8.32
    BBH B Market Vectors Biotech ETF 8.21
    VIRS B Pacer BioThreat Strategy ETF 7.61
    View all Regeneron ETFs...
    Compare ETFs
    Compare FPX to BBH Compare IBB to VIRS Compare IBBQ to IBB

        Regeneron Stocks Recent News

        Date Stock Title
        Jul 3 SNY Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
        Jul 3 SNY Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
        Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
        Jul 3 REGN Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
        Jul 3 SNY Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
        Jul 3 SNY Sanofi, Regeneron win EU label expansion for Dupixent in COPD
        Jul 3 REGN Sanofi, Regeneron win EU label expansion for Dupixent in COPD
        Jul 3 SNY EMA approves Sanofi’s Dupixent for COPD treatment in adults
        Jul 3 SNY Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
        Jul 3 SNY Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
        Jul 3 REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
        Jul 2 REGN Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
        Jul 2 REGN Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
        Jul 2 SNY Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
        Jul 1 SNY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
        Jul 1 SNY Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
        Jul 1 REGN Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
        Jul 1 SNY Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
        Jul 1 SNY Sanofi reports findings from Phase II relapsing MS treatment trial
        Jul 1 SNY Sanofi eyes German insulin investment of up to $1.6 billion, source says
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development
        Regeneron

        Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

        More about Regeneron
        Browse All Tags